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TNFECIION %WM THE HUMAN T LYMPHOTROPIC virus type I (HTLV-I), a virus associated with two diseases, 
adult T-cell leukemia lyriphornal and tropical spastic paraparesis/HTLV-I associated myelopathy,2 is 
prevalent in Panama' and Colombia.' To determine if HTLV-I is present in neighboring Costa Rica, we tested 
436 sera from women who participated, between 1984 and 198.5, in a case-control study of cervical cancer in 
Costa Rica.' These sera were all that were still available to us from the 765 collected from control participants 
in the study. Study participants had all been interviewed and tested for several serologic markers of sexually 
transmitted diseases (STDs). 
Testedwomen-Were-similar to nontested control participants for age (range 25-59 years), ethnic group 
(predominantly caucasians and hispanics), sexual histories (measured by age at first sexual activity and 
lifetime number of sex partners), herpes simplex type 2 (HSV2) seroprevalence, and histories of STDs. All 
436 sera were screened by a commercial HTLV-I enzyme-linked inununosorbent assay (ELISA) (Dupont 
Co., Wilmington, DE); all repeatably reactive sera we-Fe.fuTrther tested by Western blot; sera with suspected 
HTLV-I reactivity on Western blot but not fulfilling the criteria for HTLV-1 seropositivity (reactivity to p24 
and an env gene product)6 were further tested by radioimmunoprecipitation assay. Seven sera (1.6%) were 
repeatably reactive by ELISA; 3 (0.68%) were positive for HTLV-I antibodies (to both p24 and gp46/or 
gp68); of the remaining ELISA reactive, I had reactivity top 19 only on Western blotting and 3 had no Western 
blot reactivity. The 3 HTLV-I-seropositive women were older (mean age 48) than HTLV-I seronegative 
women (mean age 40, p = NS median two-sample test); they tended to be less educated and none lived in the 
densely populated capital area. A113 were caucasian and they lived in different parts of the country; all 3 had 
lived, as children, in the same county (Canton). While none gave a history of any STD, 2 were reactive for 
syphilis by rnicrohemagglutination assay for antibody to Treponema pailidum (MHATP), compared with 3I 
of 432 (7.2%) HTLV-I-seronegative women; all 3 were positive for HSV-2 antibodies, as were 196 of 426 
(469) HTLV-I-seronegative women; and all 3 were seropositive for Chlamydia (titer 16), as were 56.1% 
of HTLV-I-seronegative women. 
Triour knowledge, this report is the first to document HTLV-I seroprevalence in Costa Rica. A female 
predominance of HTLV-I seropositivity has been noted in virtually all endemic areas: by testing only women. 
we therefore most likely obtained a maximal estimate of the seroprevalence of HTLV-1 in Costa Rica. which 
appearJo be less than 1%. Our 0.68% rate is much lower than the rates that have been reported for other 
-countries in the area including neighboring Panama.' This difference in rates is due in part to the increased 
specificity of the HTLV-I serologic assays that we used; in fact, our rate for Costa Rica is simirar to current 
estimates for Panama (W. Reeves, personal communication); the difference in rates may also be related to 
other differences between the populations of these countries. Our numbers arc too small to allow any 
evaluation of risks; however, the relatively older age of the HTLV-1-seropositive women and the association 
with STD markers are consistent with a sexual mode of transmission.1  
'Centers for Disease Control, Atlanta, Georgia. 
=University of Costa Rica Institute for Health Research IENISA), San Jose, Costa Rica. 
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